Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News (Page 17)
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
April 3, 2018 AstraZeneca today announced the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin...
FDA Approves Toujeo (insulin glargine) Max SoloStar
BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting...
FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...
FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...
FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...
FDA Approves Admelog (insulin lispro) Rapid-Acting "Follow-On" Insulin Product to Treat Diabetes
December 11, 2017 – The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and...
Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
December 5, 2017 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Ozempic (semaglutide) injection 0.5 mg or 1 mg, a...
FDA Medwatch Alert: Riomet (Metformin Hydrochloride Oral Solution): Recall - Microbial Contamination
ISSUE: Sun Pharmaceutical Industries is recalling two lots of Riomet (Metformin Hydrochloride Oral Solution), which were found to be contaminated with Scopulariopsis brevicaulis. Use of the affected...
FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes
23 October 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of By...
Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin
PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting...
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...
FDA Medwatch Alert: Canagliflozin (Invokana, Invokamet): Drug Safety Communication - Increased Risk of Leg and Foot Amputations
ISSUE: Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and...
FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
28 February 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2...
Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes
PLAINSBORO, N.J., Dec. 19, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for...
FDA Medwatch Alert: Pioglitazone-containing Medicines: Drug Safety Communication - Updated FDA Review, Increased Risk of Bladder Cancer
ISSUE: As a result of an updated review, the FDA has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Victoza, Lantus, Mounjaro, Trulicity, glipizide, semaglutide, Rybelsus, view more... Lantus Solostar, Humalog, Farxiga, Novolog, Jardiance, Janumet, insulin glargine, Januvia, insulin lispro, Bydureon, Tresiba, Levemir, liraglutide, Invokana, Glucophage, Humulin N, insulin degludec